| Outcome Measures: |
Primary: AUCt of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337, AUCt: Area under the concentration-time curve, 0(predose)~72 hours|Cmax of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337, Cmax: Maximum plasma concentration of the drug, 0(predose)~72 hours | Secondary: AUCinf each main component or the metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337, AUCinf: Area under the concentration-time curve from zero up to ∞, 0(predose)~72 hours|tmax each main component or the metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337, tmax: Time to maximum plasma concentration, 0(predose)~72 hours|AUCt/AUCinf each main component or the metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337, AUCt/AUCinf: AUCt/AUCinf Ratio, 0(predose)~72 hours|t1/2 each main component or the metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D012, D326, D337, t1/2: Terminal elimination half-life, 0(predose)~72 hours|AUCt of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D326, D337, AUCt: Area under the concentration-time curve, 0(predose)~72 hours|Cmax of each main component or metabolite of the component after single dose of CKD-386 F1, CKD-386 F2 and D326, D337, Cmax: Maximum plasma concentration of the drug, 0(predose)~72 hours
|
